Skip to main content

Table 4 Factors of gastrointestinal perforation stratified by fluoroquinolones subgroup in different tracking period by using Cox regression

From: The incidence of collagen-associated adverse events in pediatric population with the use of fluoroquinolones: a nationwide cohort study in Taiwan

Tracking period

Fluoroquinolones subgroup

Populations

Events

PDs

Rate (per 105 PDs)

Adjusted HR

95% CI

95% CI

P

Adjusted HR

95% CI

95% CI

P

3-day

Without

133,684

2

23,707,602.75

0.01

Reference

   

Reference

   

With

33,421

0

5,940,776.06

0.00

0.000

0.995

    

 Levofloxacin

653

0

112,735.69

0.00

    

0.000

0.960

 Ciprofloxaxin

1843

0

316,411.56

0.00

    

0.000

0.978

 Moxifloxacin

139

0

24,500.00

0.00

    

0.000

0.988

 Gemifloxacin

12

0

2160.00

0.00

    

0.000

0.998

 Norfloxacin

7041

0

1,261,596.87

0.00

    

0.000

0.996

 Ofloxacin

23,733

0

4,223,371.94

0.00

    

0.000

0.990

7-day

Without

133,684

6

23,707,602.75

0.03

Reference

   

Reference

   

With

33,421

1

5,940,776.06

0.02

0.512

0.080

27.426

0.756

    

 Levofloxacin

653

0

112,735.69

0.00

    

0.000

0.982

 Ciprofloxaxin

1843

0

316,411.56

0.00

    

0.000

0.979

 Moxifloxacin

139

0

24,500.00

0.00

    

0.000

0.993

 Gemifloxacin

12

0

2160.00

0.00

    

0.000

0.986

 Norfloxacin

7041

0

1,261,596.87

0.00

    

0.000

0.978

 Ofloxacin

23,733

1

4,223,371.94

0.02

    

0.776

0.114

72.301

0.442

14-day

Without

133,684

10

23,707,602.75

0.04

Reference

   

Reference

   

With

33,421

3

5,940,776.06

0.05

1.025

0.044

1.356

0.111

    

 Levofloxacin

653

0

112,735.69

0.00

    

0.000

0.986

 Ciprofloxaxin

1843

1

316,411.56

0.32

    

1.572

0.052

7.166

0.678

 Moxifloxacin

139

0

24,500.00

0.00

    

0.000

0.995

 Gemifloxacin

12

0

2160.00

0.00

    

0.000

0.986

 Norfloxacin

7041

1

1,261,596.87

0.08

    

1.342

0.020

6.988

0.501

 Ofloxacin

23,733

1

4,223,371.94

0.02

    

0.427

0.035

4.972

0.494

28-day

Without

133,684

14

23,707,602.75

0.06

Reference

   

Reference

   

With

33,421

4

5,940,776.06

0.07

1.137

0.090

1.498

0.157

    

 Levofloxacin

653

0

112,735.69

0.00

    

0.000

0.978

 Ciprofloxaxin

1843

1

316,411.56

0.32

    

1.266

0.028

2.999

0.267

 Moxifloxacin

139

0

24,500.00

0.00

    

0.000

0.978

 Gemifloxacin

12

0

2160.00

0.00

    

0.000

0.964

 Norfloxacin

7041

1

1,261,596.87

0.08

    

2.052

0.184

22.485

0.532

 Ofloxacin

23,733

2

4,223,371.94

0.05

    

0.307

0.555

1.752

0.188

3-month

Without

133,684

45

23,707,602.75

0.19

Reference

   

Reference

   

With

33,421

12

5,940,776.06

0.20

1.049

0.156

1.925

0.198

    

 Levofloxacin

653

0

112,735.69

0.00

    

0.000

0.952

 Ciprofloxaxin

1843

1

316,411.56

0.32

    

1.076

0.013

1.972

0.129

 Moxifloxacin

139

0

24,500.00

0.00

    

0.000

0.978

 Gemifloxacin

12

0

2160.00

0.00

    

0.000

0.986

 Norfloxacin

7041

3

1,261,596.87

0.24

    

1.472

0.402

5.411

0.524

 Ofloxacin

23,733

8

4,223,371.94

0.19

    

0.390

0.145

1.786

0.379

6-month

Without

133,684

68

23,707,602.75

0.29

Reference

   

Reference

   

With

33,421

17

5,940,776.06

0.29

1.330

0.778

2.276

0.255

    

 Levofloxacin

653

0

112,735.69

0.00

    

0.000

0.975

 Ciprofloxaxin

1843

1

316,411.56

0.32

    

1.402

0.197

10.121

0.702

 Moxifloxacin

139

0

24,500.00

0.00

    

0.000

0.966

 Gemifloxacin

12

0

2160.00

0.00

    

0.000

0.973

 Norfloxacin

7041

3

1,261,596.87

0.24

    

0.911

0.348

3.526

0.813

 Ofloxacin

23,733

13

4,223,371.94

0.31

    

1.442

0.793

2.601

0.199

  1. PDs Person-days, Adjusted HR Adjusted hazard ratio: Adjusted for the variables listed in Table 2, CI Confidence interval